Antibiotic therapy for community-acquired pneumonia with septic shock: Follow the guidelines

Critical Care Medicine

Volumn 35, Issue 6, 2007, Pages 1617-1618

  Blot, Stijn ^a   Depuydt, Pieter ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Antibiotic therapy; Community acquired pneumonia; Intensive care unit; Mortality; Outcome

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG INDICATION; EDITORIAL; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; INTENSIVE CARE; MORTALITY; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEPTIC SHOCK; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; SURVIVAL;

ANTI-BACTERIAL AGENTS; BACTEREMIA; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY, COMBINATION; GUIDELINE ADHERENCE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES; SHOCK, SEPTIC; SURVIVAL ANALYSIS;

EID: 34249299101     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000266825.19629.BA     Document Type: Editorial

References (14)

1. Houck PM, Bratzler DW, Nsa W, et al: Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004; 164:637-644
2. Rello J, Rodriguez A, Torres A, et al: Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 2006; 27:1210-1216
3. Mandell LA, Wunderink RG, Anzueto A, et al: Infectious diseases society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2):S27-S72
4. Aspa J, Rajas O, Rodriguez de Castro F, et al: Drug-resistant pneumococcal pneumonia: Clinical relevance and related factors. Clin Infect Dis 2004; 38:787-798
5. Waterer GW, Somes GW, Wunderink RG: Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161:1837-1842
6. Waterer GW: Monotherapy versus combination antimicrobial therapy for pneumococcal pneumonia. Curr Opin Infect Dis 2005; 18:157-163
7. Rodríguez A, Mendia A, Sirvent JM, et al: Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007; 35:1493-1498
8. Waterer GW, Rello J: Choosing the right combination therapy in severe community-acquired pneumonia. Crit Care 2006; 10:115
9. Arnold FW, Summersgill JT, Lajoie AS, et al: A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 2007
10. Lin E, Stanek RJ, Mufson MA: Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumoniae in vitro. Antimicrob Agents Chemother 2003; 47:1151-1153
11. Dellinger RP, Carlet JM, Masur H, et al: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004; 30:536-555
12. Majumdar SR, McAlister FA, Eurich DT, et al: Statins and outcomes in patients admitted to hospital with community acquired pneumonia: Population based prospective cohort study. BMJ 2006; 333:999
13. Thomsen RW: The lesser known effects of statins: Benefits on infectious outcomes may be explained by "healthy user" effect. BMJ 2006; 333:980-981
14. Manson JE, Hsia J, Johnson KC, et al: Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349:523-534